570 related articles for article (PubMed ID: 27311528)
1. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF.
Chan KE; Giugliano RP; Patel MR; Abramson S; Jardine M; Zhao S; Perkovic V; Maddux FW; Piccini JP
J Am Coll Cardiol; 2016 Jun; 67(24):2888-99. PubMed ID: 27311528
[TBL] [Abstract][Full Text] [Related]
2. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
3. A systematic review of direct oral anticoagulant use in chronic kidney disease and dialysis patients with atrial fibrillation.
Feldberg J; Patel P; Farrell A; Sivarajahkumar S; Cameron K; Ma J; Battistella M
Nephrol Dial Transplant; 2019 Feb; 34(2):265-277. PubMed ID: 29509922
[TBL] [Abstract][Full Text] [Related]
4. Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?
Mlodawska E; Lopatowska P; Malyszko J; Banach M; Sobkowicz B; Covic A; Tomaszuk-Kazberuk A
Int Urol Nephrol; 2018 Sep; 50(9):1633-1642. PubMed ID: 29785661
[TBL] [Abstract][Full Text] [Related]
5. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763
[TBL] [Abstract][Full Text] [Related]
6. [NOACs and Chronic kidney disease].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Mar; 34(Suppl 69):188-204. PubMed ID: 28682039
[TBL] [Abstract][Full Text] [Related]
7. Non-vitamin K oral anticoagulants are non-inferior for stroke prevention but cause fewer major bleedings than well-managed warfarin: A retrospective register study.
Sjögren V; Byström B; Renlund H; Svensson PJ; Oldgren J; Norrving B; Själander A
PLoS One; 2017; 12(7):e0181000. PubMed ID: 28700711
[TBL] [Abstract][Full Text] [Related]
8. Laboratory Monitoring of Non-Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation: A Review.
Eikelboom JW; Quinlan DJ; Hirsh J; Connolly SJ; Weitz JI
JAMA Cardiol; 2017 May; 2(5):566-574. PubMed ID: 28355459
[TBL] [Abstract][Full Text] [Related]
9. Renal Outcomes in Anticoagulated Patients With Atrial Fibrillation.
Yao X; Tangri N; Gersh BJ; Sangaralingham LR; Shah ND; Nath KA; Noseworthy PA
J Am Coll Cardiol; 2017 Nov; 70(21):2621-2632. PubMed ID: 29169468
[TBL] [Abstract][Full Text] [Related]
10. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
[TBL] [Abstract][Full Text] [Related]
11. Non-vitamin K Oral Anticoagulants Versus Warfarin for Patients with Atrial Fibrillation: Absolute Benefit and Harm Assessments Yield Novel Insights.
Kumana CR; Cheung BM; Siu DC; Tse HF; Lauder IJ
Cardiovasc Ther; 2016 Apr; 34(2):100-6. PubMed ID: 26727005
[TBL] [Abstract][Full Text] [Related]
12. Oral Anticoagulation in Patients With End-Stage Kidney Disease on Dialysis and Atrial Fibrillation.
Hu A; Niu J; Winkelmayer WC
Semin Nephrol; 2018 Nov; 38(6):618-628. PubMed ID: 30413255
[TBL] [Abstract][Full Text] [Related]
13. [Not Available].
Simeon L; Wuillemin WA
Ther Umsch; 2016; 73(10):561-566. PubMed ID: 28045358
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
Hernandez I; Smith KJ; Zhang Y
Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
[TBL] [Abstract][Full Text] [Related]
15. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
16. Indirect Comparison of Novel Oral Anticoagulants in Women with Nonvalvular Atrial Fibrillation.
Moseley A; Doukky R; Williams KA; Jaffer AK; Volgman AS
J Womens Health (Larchmt); 2017 Mar; 26(3):214-221. PubMed ID: 27870603
[TBL] [Abstract][Full Text] [Related]
17. Minimizing the Risk of Bleeding with NOACs in the Elderly.
Kundu A; Sardar P; Chatterjee S; Aronow WS; Owan T; Ryan JJ
Drugs Aging; 2016 Jul; 33(7):491-500. PubMed ID: 27174293
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulation Therapy and NOACs in Heart Failure.
Thomas I; EncisoSilva J; Schlueter M; Greenberg B
Handb Exp Pharmacol; 2017; 243():515-535. PubMed ID: 28233177
[TBL] [Abstract][Full Text] [Related]
19. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban.
Stöllberger C; Finsterer J
Herz; 2015 Apr; 40 Suppl 2():140-5. PubMed ID: 25616425
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Novel Oral Anticoagulants in Patients With Atrial Fibrillation and Heart Failure: A Meta-Analysis.
Savarese G; Giugliano RP; Rosano GM; McMurray J; Magnani G; Filippatos G; Dellegrottaglie S; Lund LH; Trimarco B; Perrone-Filardi P
JACC Heart Fail; 2016 Nov; 4(11):870-880. PubMed ID: 27614940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]